SUBLIN BV, a spin-out of the healthcare branch of NanoServe BV (NSV), founded by Dr. Amina Tijani, was established in 2017 in the Netherlands. SUBLIN is developing an oral sublingually-available insulin formulation called the Sub-Lingual Insulin Modality (SLIM), as a patient-compliant, non-invasive alternative administration route for the treatment of insulin-dependent diabetes mellitus. Current insulin injections are problematic in several ways. SUBLIN provides the ultimate means to safely and comfortably administer insulin; via a pleasant fast-dissolving film under the tongue.The prevalence of diabetes is becoming a pandemic, currently affecting 9% of the global adult population. An estimated 463 million people suffered from diabetes in 2019 and this is projected to rise to 700 million by 2045. The insulin market reached around $50 billion last year with a sizeable compound annual growth rate (CAGR) of 16.9% towards 2023.The applied technology platform has the capabilities to encapsulate small molecules, peptides as well as large proteins which allows SUBLIN to develop a pipeline of many ‘orally’ available drug products for diabetes and metabolic disorders. SLIM products showed excellent safety profiles and very high insulin bioavailability in diabetes animal models, while ruling out the risk of hypoglycemia. SLIM technology has been filed for patent protection in 2020. SUBLIN was backed by a round A investment in 2019 and secured round A+ in 2020. Currently, it is raising a Series B1 round of €10 Mio to enable its GMP-manufacturing and to initiate clinical first-in-human studies later this year.